1691. Is there Failure to Screen for Hepatitis C in Newborns Suffering from Neonatal Abstinence Syndrome?
Session: Oral Abstract Session: Hepatitis B and C Across the Lifespan
Friday, October 6, 2017: 2:15 PM
Room: 05AB
Background: Enormous advances in treating/curing patients suffering from Hepatitis C (HepC) infection have occurred; resulting in many states mandating screening for HepC for older individuals. Unfortunately, no protection of screening exists for newborns. In Kentucky, rates of HepC among pregnant women are the second highest within the U.S., which has been associated to high intravenous drug use. Infants born to those women are at risk of HepC infection and other conditions such as neonatal abstinence syndrome (NAS). The current study examined the rate of HepC screening in a high-risk cohort (newborns suffering from NAS) and it’s impact on policy-making for this vulnerable population.

Methods: Kentucky Medicaid records, from 2015, were obtained to develop a detailed demographic, behavioral, clinical, and diagnostic data set (n=152,749). NAS was defined by ICD-9 code 779.5 and ICD-10 code P96.1. HepC screening was defined by CPT codes (CPT 87520 [HCV, direct probe], 87521 [HCV, amplified probe], and 87522 [HCV RNA, Quantitative] or antibody [CPTs 86803-4]). Initially a descriptive study was performed, then multiple logistic regression techniques were used to test what variables impacted the odds of not being screened for HepC.

Results:A total of n=1234 newborns with NAS were identified. The majority showed signs of NAS within 24 hours (64%), were white (68%) and were admitted to the hospital for an average of 24.8 days. Only one-in-three newborns with NAS (n=412, 33.4%) were screened for HepC. Non-whites (OR=1.58, 95% CI 1.45-1.71, p<0.001) and those living in non-urban areas (OR=1.42, 95% CI 1.28-1.56, p<0.001) were the only study variables to significantly impact the odds of not being screened for HepC (for newborns suffering from NAS).

Conclusion:A high-risk and vulnerable population for HepC may not be getting screened for HepC and thus are being underserved by the health care system. Non-whites and those in rural areas are the most affected. Solutions and policies need to be focused on this population and area where screening is lacking. Optimization of maternal screening for HepC is crucial in high risk populations.

John Myers, PhD MSPH1, Michael Smith, MD, MSCE2, Claudia Espinosa, MD, MSc3, Charles Woods, MD, MS, FIDSA, FSHEA, FPIDS1,4 and Scott Duncan, MD, MHA3, (1)University of Louisville, Louisville, KY, (2)Pediatric Infectious Diseases, University of Louisville, LOUISVILLE, KY, (3)Pediatrics, University of Louisville, Louisville, KY, (4)Pediatrics, University of Louisville School of Medicine, Louisville, KY


J. Myers, None

M. Smith, None

C. Espinosa, None

C. Woods, None

S. Duncan, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.